Which of the following is a side effect of binimetinib and encorafenib?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Study for the Pharmacology Presentation Drugs Test. Delve into flashcards and multiple choice questions with hints and explanations. Gear up for examination success!

Multiple Choice

Which of the following is a side effect of binimetinib and encorafenib?

Explanation:
New skin cancers are a notable side effect of this drug combination. A BRAF inhibitor like encorafenib can cause paradoxical activation of the MAPK pathway in skin cells that don’t have a BRAF mutation, which can drive the development of non-melanoma skin cancers such as squamous cell carcinomas and keratoacanthomas. Adding a MEK inhibitor like binimetinib slows the pathway downstream and reduces this risk, but it does not eliminate it entirely, so new skin cancers can still occur with this regimen. Other listed effects aren’t as characteristic for this combination.

New skin cancers are a notable side effect of this drug combination. A BRAF inhibitor like encorafenib can cause paradoxical activation of the MAPK pathway in skin cells that don’t have a BRAF mutation, which can drive the development of non-melanoma skin cancers such as squamous cell carcinomas and keratoacanthomas. Adding a MEK inhibitor like binimetinib slows the pathway downstream and reduces this risk, but it does not eliminate it entirely, so new skin cancers can still occur with this regimen. Other listed effects aren’t as characteristic for this combination.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy